Vistagen Therapeutics, Inc.
VTGN· Nasdaq
VTGNVistagen Therapeutics, Inc.
Filed Feb 14, 2014 · 10-Q · 45 days after period end · 0001415889-14-000587
| Metric | Q3 2014 | Q3 2010 |
|---|---|---|
| Revenue | — | $584.77K |
| Net Income | $131.00K | -$3.39M |
| EPS Diluted | -$0.02 | -$0.65 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
ended Dec 31, 2013 · filed Feb 14, 2014 · 45 d after period end
